Joshua Greene, MD
Retina Specialist · Philadelphia, PANPI 1619978756
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $315,014 of the $393,996 with a category attached, or 80.0%. 17 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 45.3% of the total. Among retina specialist clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 377 payments — averaging $1045.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$178K
- Genentech USA, Inc.$115K
- Apellis Pharmaceuticals, Inc.$79K
- Alimera Sciences, Inc.$12K
- AbbVie$7K
- Smith+Nephew$1K
- plus $1K from 11 others
What the payments were for
- Consulting fees$21,8966%
- Speaking & faculty fees$315,01480%
- Travel & lodging$45,06411%
- Food & beverage$12,0213%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 118 | $178,391 |
| Genentech USA, Inc. | 93 | $114,972 |
| Apellis Pharmaceuticals, Inc. | 66 | $78,955 |
| Alimera Sciences, Inc. | 39 | $12,243 |
| AbbVie(2 entities) | 21 | $7,354 |
| Smith+Nephew | 8 | $1,052 |
| Stryker | 2 | $247 |
| ANI Pharmaceuticals, Inc. | 11 | $228 |
| Sandoz | 6 | $184 |
| Coherus Oncology, Inc. | 3 | $130 |
| Astellas Pharma US Inc | 2 | $40 |
| Bausch & Lomb Americas Inc. | 2 | $39 |
| Novartis | 2 | $37 |
| Eyepoint US, Inc. | 1 | $37 |
| Samsara Vision | 1 | $34 |
| Harrow Eye, LLC | 1 | $29 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$393,996 in reported general payments places this provider in the 95th percentile of 43 retina specialist providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketorolac Tromethamine | 315 | $4,542 |
| Prednisolone Acetate | 103 | $3,598 |
| Brimonidine Tartrate | 30 | $1,617 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 75 | $1,353 |
| Latanoprost | 138 | $1,353 |
| Atropine Sulfate | 21 | $487 |
| Dorzolamide Hcl | 20 | $385 |
| Ciprofloxacin Hcl | 15 | $151 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Philadelphia
- Brian VanderbeekPhiladelphia$14K
- Albert MaguirePhiladelphia$9K
- Hugo LinaresPhiladelphia$7K
- Benjamin KimPhiladelphia$5K
- Tomas AlemanPhiladelphia$3K
- Robert CarrollPhiladelphia$1K
- Drew ScolesPhiladelphia$519
- Juan GrunwaldPhiladelphia$508
- Alexander BruckerPhiladelphia$86
- William FosterPhiladelphia$28
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.